Endocrine Abstracts

Introduction: Somatostatinanalogues (SSAs) are the largest contributor to the direct medical cost of acromegaly management worldwide. The aim of this review was to expose our experience and report available evidence on the effectiveness of SSAs in the treatment of acromegaly.

Methods: This is a retrospective study including ten acromegalic patients followed in the Endocrinology - Diabetology Department at Mohamed VI University Hospital in Oujda, Morocco.

Results: The mean age at time of diagnosis was 49 years with a female predominance. The median delay to diagnosis was 8 years. Etiological diagnosis was pituitary adenoma in all our patients, macroadenoma in 9 patients and microadenoma in one patient. Eight patients had received medical treatment with SSAs: Lanreotide LP 120 mg. This treatment was given pre-operatively in four patients with non-invasive adenoma and in three patients with second line after incomplete tumor removal with persistent tumor residue. The pre-therapeutic evaluation had objected a vesicular sludge in one patient and a lithiasis of the main biliary tract in one patient. Treatment with SSAs has allowed IGF1 to be normalized in 62.5% of cases. During follow up, there was a sides effects, the occurrence of vesicular lithiasis were complicated by cholecystitis in one patient and transit disorders in another patient.

Conclusion: Lanreotide is the only SSAs available in Morocco. It represents a particularly interesting alternative in case of somatotropic hypersecretion after surgery or in inoperable forms.